Cited by 723HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Open access

Venter, Willem D.F., Moorhouse, Michelle, Sokhela, Simiso, Fairlie, Lee, Mashabane, Nkuli, Masenya, Masebole, Serenata, Celicia, Akpomiemie, Godspower, Qavi, Ambar, Chandiwana, Nomathemba, Norris, Shane, Chersich, Matthew, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Vos, Alinda, McCann, Kaitlyn, Simmons, Bryony, Hill, Andrew·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1902824

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries. METHODS: We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter. The primary end point was the percentage of patients with a 48-week HIV-1 RNA level of less than 50 copies per milliliter (as determined with the Snapshot algorithm from the Food and Drug Administration; noninferiority margin, -10 percentage points). We report the primary (48-week) efficacy and safety data. RESULTS: A total of 1053 patients underwent randomization from February 2017 through May 2018. More than 99% of the patients were black, and 59% were female. The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter. At week 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, findings that indicate that the DTG-containing regimens were noninferior to the standard-care regimen. The number of patients who discontinued the trial regimen was higher in the standard-care group than in the other two groups. In the per-protocol population, the standard-care regimen had equivalent potency to the other two regimens. The TAF-based regimen had less effect on bone density and renal function than the other regimens. Weight increase (both lean and fat mass) was greatest in the TAF-based group and among female patients (mean increase, 6.4 kg in the TAF-based group, 3.2 kg in the TDF-based group, and 1.7 kg in the standard-care group). No resistance to integrase inhibitors was identified in patients receiving the DTG-containing regimens. CONCLUSIONS: Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen. (ADVANCE ClinicalTrials.gov number, NCT03122262.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1902824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe
Mika Kivimaki, B., Kuosma, E., Ferrie, J. E., Luukkonen, R. A., Nyberg, S. T., Alfredsson, L. S., Batty, G. D., Brunner, E. J., Fransson, E. I., Goldberg, M., et al. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30074-9 · Cited by 695
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax, P. E., Pozniak, A., Montes, M., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 394
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Zash, R., Makhema, J. M., & Shapiro, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807653 · Cited by 379
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens
Norwood, J., Turner, M. M., Bofill, C., Rebeiro, P. F., Shepherd, B. E., Bebawy, S. S., Hulgan, T., Raffanti, S. P., Haas, D. W., Sterling, T. R., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001525 · Cited by 285
Brief Report
Walmsley, S. L., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, É., Khuong-Josses, M.-A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000790 · Cited by 225
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Kanters, S., Vitória, M., Doherty, M. C., Socias, M. E., Ford, N. P., Forrest, J. I., Popoff, E., Bansback, N. J., Nsanzimana, S., Thorlund, K., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30091-1 · Cited by 210
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
Bakal, D. R., Coelho, L. E., Luz, P. M., Clark, J. L., Boni, R. B. D., Cardoso, S. W., Veloso, V. G., Lake, J. E., & Grinsztejn, B. G. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky145 · Cited by 188
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Wohl, D. A., Yazdanpanah, Y., Baumgarten, A., Clarke, A. E., Thompson, M., Brinson, C. C., Hagins, D. P., Ramgopal, M. N., Antinori, A., Wei, X., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30077-3 · Cited by 168

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 2

Doherty M. New directions in the 2015 WHO Consolidated ARV Guidelines: testing new directions in treatment and measuring impact. Presented at the Eighth International AIDS Society Conference Vancouver BC Canada July 19–22 2015.
Beyrer C, Pozniak A. HIV drug resistance. N Engl J Med 2018;378:875-875.29490186

Sorted by citations

Items 201–300 of 719

Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan
Hongo, H., Nagao, T., Nakamura, K., Kitaichi, T., Maeno, Y., Tokunaga, T., Fukuda, A., & Koga, I. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01842-3 · Cited by 17
Antiretroviral Therapy and Cardiovascular Risk in People With HIV in the United States—An Updated Analysis
Parra-Rodriguez, L., Sahrmann, J. M., Butler, A. M., Olsen, M. A. A., Powderly, W. G., & O’Halloran, J. A. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae485 · Cited by 17
Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa
Roozen, G. V. T., Vos, A. G., Tempelman, H. A., Venter, F., Grobbee, D. E., Scheuermaier, K. D., & Klipstein‐Grobusch, K. (2019) · HIV Medicine · doi:10.1111/hiv.12831 · Cited by 17
Self-citation
Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
Hauser, A., Kusejko, K., Johnson, L. F., Günthard, H. F., Riou, J., Wandeler, G., Egger, M., & Kouyos, R. D. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003397 · Cited by 17
Relationship between Endothelial Function, Antiretroviral Treatment and Cardiovascular Risk Factors in HIV Patients of African Descent in South Africa: A Cross-Sectional Study
Nkeh-Chungag, B. N., Goswami, N., Engwa, G. A., Sewani-Rusike, C. R., Mbombela, V., Webster, I., Boever, P. D., Kessler, H. H., Stelzl, E., & Strijdom, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030392 · Cited by 17
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa
Steegen, K., Moorhouse, M. A., Wensing, A. M. J., Venter, W. D., & Hans, L. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25706 · Cited by 17
Self-citation
Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States
Mounzer, K., Brunet, L., Hsu, R. K., Fusco, J. S., Vannappagari, V. X., Henegar, C., Wyk, J. A. V., Crawford, M., Lo, J., & Fusco, G. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0287 · Cited by 17
Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus
Asundi, A., Olson, A. J., Jiang, W., Varshney, S. P., White, L. F., Sagar, M., & Lin, N. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0091 · Cited by 17
HIV: how to manage dyslipidaemia in HIV
Lee, D. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-8-7 · Cited by 17
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
Compagnucci, A., Chan, M. K., Saïdi, Y., Cressey, T. R., Bamford, A., Riault, Y., Coelho, A., Nolan, A., Chalermpantmetagul, S., Morkunaite, G., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102025 · Cited by 17
Functioning Problems Associated with Health Conditions with Greatest Disease Burden in South Africa: A Scoping Review
Charumbira, M. Y., Berner, K., & Louw, Q. A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315636 · Cited by 16
Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study
Hirigo, A. T., Yilma, D., Astatkie, A., & Debebe, Z. Y. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2242250 · Cited by 16
Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function
Quesada‐López, T., Cereijo, R., Blasco‐Roset, A., Mestres‐Arenas, A., Prieto, P., Domingo, J. C., Villarroya, F., Domingo, P., & Giralt, M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.116010 · Cited by 16
Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives
Markakis, K., Tsachouridou, Ο., Georgianou, E., Pilalas, D., Nanoudis, S., & Metallidis, S. (2024) · Life · doi:10.3390/life14111367 · Cited by 16
The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study
Lippman, S. A., Mooney, A. C., Puren, A. J., HUNT, G. M., Grignon, J. S., Prach, L. M., Gilmore, H. J., Truong, H. M., Barnhart, S., & Liegler, T. J. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4933-z · Cited by 16
Nothing is perfect: the safety issues of integrase inhibitor regimens
Scévola, S. C., Tiraboschi, J. M., & Podzamczer, D. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1764531 · Cited by 16
Electrocardiographic and echocardiographic abnormalities in urban African people living with HIV in South Africa
Roozen, G. V. T., Meel, R., Peper, J., Venter, F., Barth, R. E., Grobbee, D. E., Klipstein‐Grobusch, K., & Vos, A. G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244742 · Cited by 16
Self-citation
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication
Shah, S., & Hill, A. M. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000671 · Cited by 16
Self-citation
Linkage to intensive adherence counselling among HIV-positive persons on ART with detectable viral load in Gomba district, rural Uganda
Nakalega, R., Mukiza, N., Debem, H. H., Kiwanuka, G., Kakumba, R. M., Menge, R., Kagimu, I.-K., Nakaye, C., Babirye, J. A., Kaganzi, H., et al. (2021) · AIDS Research and Therapy · doi:10.1186/s12981-021-00349-9 · Cited by 16
The Effect of Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Pregnancy on Gestational Weight Gain
Joseph, N. T., Satten, G. A., Williams, R. E., Haddad, L. B., Jamieson, D. J., Sheth, A. N., & Badell, M. L. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab994 · Cited by 16
Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps
Naidoo, A., Naidoo, K., Padayatchi, N., & Dooley, K. E. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(21)00324-6 · Cited by 16
Fibroscan–Aspartate Aminotransferase Score Predicts Liver-Related Outcomes, but Not Extrahepatic Events, in a Multicenter Cohort of People With Human Immunodeficiency Virus
Sebastiani, G., Milić, J., Kablawi, D., Gioè, C., Hinai, A. S. A., Lebouché, B., Tsochatzis, E. A., Finkel, J., Ballesteros, L. R., Ramanakumar, A. V., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad203 · Cited by 16
Antiretroviral Treatment for HIV Elite Controllers?
Ruíz-Mateos, E., Poveda, E., & Lederman, M. M. (2020) · Pathogens and Immunity · doi:10.20411/pai.v5i1.364 · Cited by 16
Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results
McCluskey, S. M., Muyindike, W. R., Nanfuka, V., Omoding, D., Komukama, N., Barigye, I. T., Kansiime, L., Tumusiime, J., Aung, T. N., Stuckwisch, A. M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae260 · Cited by 15
A Guide to Implementation Science for Phase 3 Clinical Trialists
Spall, H. G. C. V., Desveaux, L., Finch, T. L., Lewis, C. C., Mensah, G. A., Rosenberg, Y., Singh, K., Venter, F., Weiner, B. J., & Zannad, F. M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.068 · Cited by 15
Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study
Taramasso, L., Biagio, A. D., Bovis, F., Forlanini, F., Albani, E., Borjesson, R. P., & Giacomet, V. (2020) · Microorganisms · doi:10.3390/microorganisms8060864 · Cited by 15
Systems Analysis of Gut Microbiome Influence on Metabolic Disease in HIV-Positive and High-Risk Populations
Armstrong, A. J. S., Quinn, K. D., Fouquier, J., Li, S. X., Schneider, J. M., Nusbacher, N. M., Doenges, K., Fiorillo, S. P., Marden, T. J., HIGGINS, J. A., et al. (2021) · mSystems · doi:10.1128/msystems.01178-20 · Cited by 15
Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials
Fournier, A. L., Hocqueloux, L., Braun, D. L., Metzner, K. J., Kouyos, R. D., Raffi, F., Briant, A. R., Martínez, E., de Lazzari, E., Negredo, E., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac107 · Cited by 15
Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures
Ritou, E., Satta, S., Petcherski, A., Δάσκου, Μ., Sharma, M. B., Vasilopoulos, H., Murakami, E., Shirihai, O. S., & Kelesidis, T. (2023) · Metabolism · doi:10.1016/j.metabol.2022.155395 · Cited by 15
Sex Differences in HIV Infection
Altfeld, M. A., & Scully, E. P. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_3 · Cited by 15
Metabolic Syndrome in HIV/HCV Co-infected Patients
Collins, L. F., Adekunle, R. O., & Cartwright, E. J. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-00207-3 · Cited by 15
Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
Chen, Y., Hardy, H., Pericone, C. D., & Chow, W. S. (2020) · Journal of health economics and outcomes research · doi:10.36469/jheor.2020.13457 · Cited by 15
Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy
Erlandson, K. M., Wu, K., Lake, J. E., Samuels, D. C., Bares, S. H., Tassiopoulos, K., Koethe, J. R., Brown, T. T., Leonard, M. A., Benson, C. A., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002771 · Cited by 15
COVID-19 and Antiretroviral Therapies: South Africa’s Charge Towards 90–90–90 in the Midst of a Second Pandemic
Mendelsohn, A. S., & Ritchwood, T. D. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02898-y · Cited by 15
Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV
Batta, Y., King, C., Cooper, F., Johnson, J. L., Haddad, N., Boueri, M. G., DeBerry, E., & Haddad, G. E. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1118653 · Cited by 17
Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program
Kanise, H., van Oosterhout, J. J., Bisani, P., Songo, J., Matola, B. W., Chipungu, C., Simon, K., Cox, C. M., Hosseinipour, M. C., Sagno, J.-B., et al. (2023) · Viruses · doi:10.3390/v16010029 · Cited by 14
Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex
Lahiri, C. D., Mehta, C. C., Yang, Q., Maramba, T., Musonge-Effoe, J., Yang, C.-A., Dumond, J. B., Alcaide, M. L., Lake, J. E., Rubin, L. H., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae474 · Cited by 14
Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts
Tiendrebeogo, T., Malateste, K., Poda, A., Minga, A., Lahiri, C. D., Ezechi, O., Ekouévi, D. K., Ofotokun, I., & Jaquet, A. (2024) · Journal of the International AIDS Society · doi:10.1002/jia2.26371 · Cited by 14
Putting women in the centre of the global HIV response is key to achieving epidemic control!
Karim, Q. A., Havlir, D. V., & Phanuphak, N. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25473 · Cited by 14
Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy
Cyktor, J. C., Bosch, R. J., Mar, H., Macatangay, B. J. C., Collier, A. C., Hogg, E., Godfrey, C. C., Eron, J. J., McMahon, D. K., Mellors, J. W., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa373 · Cited by 14
Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s
Koethe, J. R., Moser, C., Brown, T. T., Stein, J. H., Kelesidis, T., Dubé, M. P., Currier, J. S., & McComsey, G. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab542 · Cited by 16
Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims
Tse, J. Y. M., Prajapati, G., Zhao, X., Near, A. M., & Kumar, P. N. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2239661 · Cited by 14
Metabolic implications and safety of dolutegravir use in pregnancy
Dontsova, V., Mohan, H., Blanco, C., Jao, J. K., Greene, N. D. E., Copp, A. J., Zash, R., & Serghides, L. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00141-8 · Cited by 14
Lipid Disorders in People with HIV
Sarkar, S., & Brown, T. T. (2021) · Europe PMC (PubMed Central) · Cited by 13
The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission
Yang, L. Z., Cambou, M. C., & Nielsen‐Saines, K. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00655-z · Cited by 13
Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
Kouamou, V., Washaya, T., Ndhlovu, C. E., & Manasa, J. (2023) · Viruses · doi:10.3390/v15091882 · Cited by 13
RETRACTED ARTICLE: Determinants of viral load suppression failure among HIV adults on ARV attending health care facilities: a retrospective study in Tanga region, Tanzania
Mboggo, E., Mtisi, E. L., Mushy, S. E., Mkawe, S., Ngalesoni, F. N., Muya, A., Kilimba, E., Kamugumya, D., & Mlay, B. S. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-023-08604-2 · Cited by 13
Retracted
Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV
Kousari, A., Wilson, M. P., Hawkins, K. L., Bandali, M. M., Henao‐Martínez, A. F., Gardner, E. M., & Erlandson, K. M. (2024) · HIV Research & Clinical Practice · doi:10.1080/25787489.2024.2339576 · Cited by 13
Relationship of Subcutaneous Adipose Tissue Inflammation–Related Gene Expression With Ectopic Lipid Deposition in Persons With HIV
Bailin, S. S., Gabriel, C. L., Fan, R., Ye, F., Nair, S., Terry, J. G., Carr, J. J., Silver, H. J., Wanjalla, C. N., Mashayekhi, M., et al. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002926 · Cited by 13
Antiretroviral therapy uptake and predictors of virological failure in patients with HIV receiving first-line and second-line regimens in Johannesburg, South Africa: a retrospective cohort data analysis
Gumede, S. B., Venter, F., de Wit, J. B. F., Wensing, A. M. J., & Lalla‐Edward, S. T. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054019 · Cited by 14
Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
Thimm, M. A., Livingston, A. G., Ramroop, R., & Eke, A. C. (2022) · Journal of AIDS and HIV Treatment · doi:10.33696/aids.4.026 · Cited by 13
Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out
Hickey, M. D., Wafula, E. M., Ogachi, S., Ojwando, H., Orori, G., Adede, R. O., Garraza, L. G., Petersen, M. L., Havlir, D. V., Balzer, L. B., et al. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003173 · Cited by 13
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV ‐infected people from the French Dat' AIDS cohort: A propensity score‐matched analysis
Hocqueloux, L., Menard, A., Arvieux, C., Joly, V., Becker, A., Chéret, A., Duvivier, C., Cabie, A., Delpierre, C., Allavena, C., et al. (2023) · HIV Medicine · doi:10.1111/hiv.13488 · Cited by 13
Body mass index trends and its impact of under and overweight on outcome among PLHIV on antiretroviral treatment in rural Tanzania: A prospective cohort study
Kalinjuma, A. V., Hussey, H. S., Mollel, G. J., Letang, E., Battegay, M., Glass, T. R., Paris, D. H., Vanobberghen, F. M., Weisser, M., & on behalf of the KIULARCO study group (2023) · PLoS ONE · doi:10.1371/journal.pone.0290445 · Cited by 13
Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study
Thielking, A. M., Fitzmaurice, K. P., Sewpaul, R., Chrysanthopoulou, S. A., Dike, L., Levy, D. E., Rigotti, N. A., Siedner, M. J., Wood, R., Paltiel, A. D., et al. (2024) · Journal of the International AIDS Society · doi:10.1002/jia2.26315 · Cited by 12
Dynamics of HIV PrEP use and coverage during and after COVID-19 in Germany
Schmidt, D., Duport, Y., Kollan, C., Marcus, U., Iannuzzi, S., & von Kleist, M. (2024) · BMC Public Health · doi:10.1186/s12889-024-19198-y · Cited by 12
Noninvasive Markers of Hepatic Steatosis and Fibrosis Following Integrase Strand-Transfer Inhibitor Initiation in Women With HIV
Yu, M. A., Gerig, L., Mehta, C. C., Musonge-Effoe, J., Alvarez, J. A., Ofotokun, I., Sheth, A. N., Ali, M. K., Ziegler, T. R., Yang, Q., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf049 · Cited by 12
Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine
Assoumou, L., Racine, C., Fellahi, S., Lamazière, A., Farabos, D., Béniguel, L., Bastard, J., Fève, B., Gibowski, S., Katlama, C., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002644 · Cited by 12
Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV
Huang, S., Huang, W.-C., Lin, S., Chuang, Y., Sun, H., Chang, S., Kuo, P.-H., Wu, P., Liu, W., Chiang, C., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002650 · Cited by 12
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
Kawuma, A. N., Wasmann, R. E., Sinxadi, P., Sokhela, S. M., Chandiwana, N. C., Venter, F., Wiesner, L., Maartens, G., & Denti, P. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12955 · Cited by 12
Self-citation
Sarcopenic Obesity Phenotypes in Patients With HIV: Implications for Cardiovascular Prevention and Rehabilitation
Milić, J., Calza, S., Cantergiani, S., Albertini, M., Gallerani, A., Menozzi, M., Barp, N., Todisco, V., Renzetti, S., Motta, F., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.027 · Cited by 12
The association of menopause with cardiometabolic disease risk factors in women living with and without HIV in sub-Saharan Africa: Results from the AWI-Gen 1 study
Chikwati, R. P., Jaff, N. G., Mahyoodeen, N. G., Micklesfield, L. K., Ramsay, M., Gómez-Olivé, F. X., Mohamed, S. F., Choma, S. S. R., George, J. A., & Crowther, N. J. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108069 · Cited by 12
The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV
Rojo, P., Carpenter, D., Venter, F., Turkova, A., & Penazzato, M. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25576 · Cited by 12
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens
Cindi, Z., Maartens, G., Bradford, Y., Venter, F., Sokhela, S. M., Chandiwana, N. C., Haas, D. W., & Sinxadi, P. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002661 · Cited by 12
Self-citation
Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants
Verboeket, S. O., Boyd, A. C., Wit, F. W. N. M., Verheij, E., van der Loeff, M. F. S., Kootstra, N. A., van der Valk, M., Reiss, P., & on behalf of the AGEhIV Cohort Study Group (2021) · PLoS ONE · doi:10.1371/journal.pone.0251205 · Cited by 12
Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors
Chen, Y., Anderson, D., Pericone, C. D., & Donga, P. Z. (2022) · Journal of health economics and outcomes research · doi:10.36469/001c.30184 · Cited by 12
Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
Mondleki, E., Banda, C. G., Chandiwana, N. C., Sokhela, S. M., Wiesner, L., Venter, F., Maartens, G., & Sinxadi, P. (2022) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v23i1.1452 · Cited by 11
Self-citation
Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study
Theron, A. J., Anderson, R., Madzime, M., Rossouw, T. M., Steel, H. C., Meyer, P. W. A., Cholo, M. C., Kwofie, L. L. I., Feldman, C. H., & Tintinger, G. R. (2022) · Molecules · doi:10.3390/molecules27249057 · Cited by 11
Dolutegravir resistance in sub-Saharan Africa: should resource-limited settings be concerned for future treatment?
Kamori, D., & Barabona, G. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.1253661 · Cited by 11
Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
Hsu, J., Sun, H., Chen, L.-Y., Chang, S., Chuang, Y., Huang, Y., Su, Y., Liu, W., & Hung, C. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.10.012 · Cited by 11
Effect of 2 Forms of Tenofovir on Duodenal Enterocytes—A Hypothesis for Different Effect of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide on Body Weight and Plasma Lipids
Kauppinen, K. J., Aho, I., Sjöblom, N., Tynninen, O., Suomalainen, A., Schwab, U., Zhao, F., Arkkila, P. E. T., & Sutinen, J. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae374 · Cited by 11
Immunosenescence and its related comorbidities in older people living with HIV
He, X.-Y., Wang, X., Li, S., Li, N., Li, W., Hu, Y., Guo, N., Zheng, Y., Zheng, H., & Su, B. (2024) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000134 · Cited by 11
Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria
Nwogu, J. N., Gandhi, M., Owen, A., Khoo, S., Taiwo, B., Olagunju, A., Berzins, B., Okochi, H., Tallerico, R., Robertson, K., et al. (2021) · AIDS · doi:10.1097/qad.0000000000002984 · Cited by 11
Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS
Jao, J. K., Balmert, L. C., Sun, S., McComsey, G. A., Brown, T. T., Tien, P. C., Currier, J. S., Stein, J. H., Qiu, Y., LeRoith, D., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab663 · Cited by 11
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial
Jamieson, L., Serenata, C., Makhubele, L., Sokhela, S., Mashabane, N., Akpomiemie, G., Johnson, L. F., Venter, W. D. F., & Meyer‐Rath, G. (2021) · AIDS · doi:10.1097/qad.0000000000003068 · Cited by 11
Self-citation
Type and timing of antiretroviral therapy during pregnancy: Impact on risk of preterm delivery and small‐for‐gestational age births in Canada, a retrospective cohort study
Schneidman, J., Lee, T., Sauve, L. J., Brophy, J. C., Bitnun, A., Singer, J., Money, D., Kakkar, F., Boucoiran, I., & (CPHSP), F. T. C. P. H. S. P. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14705 · Cited by 11
Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population
Mavarani, L., Albayrak-Rena, S., Potthoff, A. V., Hower, M., Dolff, S., Sammet, S., Maischack, F., Schadendorf, D., Schmidt, B., Eßer, S., et al. (2023) · Infection · doi:10.1007/s15010-023-02009-8 · Cited by 11
Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study
Marín, J. A. M., Velasco-Penagos, J. C., Mauss, S., Rodríguez-Evaristo, M. S., Pérez‐Barragán, E., Villa-Platas, J., Barragán-Huerta, L., & Gaytán‐Martínez, J. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231196605 · Cited by 11
Does HIV infection modify the relationship between pre‐pregnancy body mass index and adverse birth outcomes?
Bengtson, A. M., Phillips, T. K., le Roux, S. M., Brittain, K., Zerbe, A., Madlala, H. P., Malaba, T. R., Petro, G. A., Abrams, E. J., & Myer, L. (2020) · Paediatric and Perinatal Epidemiology · doi:10.1111/ppe.12688 · Cited by 11
Self-citation
Weighing in on the Role of Integrase Strand Transfer Inhibitors (INSTIs) on Weight Gain: Fact or Fiction?
Pérez, S. E., Chow, S. P., Kania, A. T., Goldberg, R. N., & Badowski, M. E. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00727-w · Cited by 11
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome
Calza, L., Colangeli, V., Borderi, M., Beci, G., Esposito, F., Bon, I., Re, M. C., & Viale, P. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1823468 · Cited by 11
Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025
Moschese, D., Esvan, R., Fusetti, C., Barchi, V., Cossu, M. V., Giacinta, A., Lazzarin, S., Terracini, G., Caruso, F., Micheli, G., et al. (2025) · Eurosurveillance · doi:10.2807/1560-7917.es.2025.30.39.2500739 · Cited by 10
A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)
Koethe, J. R., Lake, J. E., Kantor, A., Smeaton, L. M., Erlandson, K. M., Moran, L. E., Belaunzarán-Zamudio, P. F., LANDAY, A. L., Campo, R., Debroy, P., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag196 · Cited by 10
Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho
Brown, J. A., Nsakala, B. L., Mokhele, K., Rakuoane, I., Muhairwe, J. A., Glass, T. R., Amstutz, A., Tschumi, N., Belus, J. M., Klimkait, T., et al. (2022) · HIV Medicine · doi:10.1111/hiv.13352 · Cited by 10
Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
da Silva, G. J., Mendicino, C. C. P., de Pádua, C. A. M., & Tupinambás, U. (2023) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2023ao0156 · Cited by 10
Comprehensive Analysis of HIV-1 Integrase Resistance-Related Mutations in African Countries
Branda, F., Giovanetti, M., Sernicola, L., Farcomeni, S., Ciccozzi, M., & Borsetti, A. (2024) · Pathogens · doi:10.3390/pathogens13020102 · Cited by 10
Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir-Based Regimen in Togo
Konu, Y. R., Takassi, E. O., Peytavin, G., Dapam, N., Damond, F., Adama, O. I. W., Zaidi, M., Yusti, A.-M. F., Dagnra, C. A., Hingrat, Q. L., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae278 · Cited by 10
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa
Manne‐Goehler, J., Fabian, J., Sokhela, S. M., Akpomiemie, G., Rahim, N. E., Lalla‐Edward, S. T., Brennan, A. T., Siedner, M. J., Hill, A. M., & Venter, F. (2024) · Journal of the International AIDS Society · doi:10.1002/jia2.26268 · Cited by 10
Self-citation
Switch to Integrase Strand Transfer Inhibitors During the Menopausal Transition Is Associated With Accelerated Body Composition Change in Women With HIV
Abelman, R. A., Ma, Y., Mehta, C. C., Yang, Q., Xia, F., Brock, J. B., Alcaide, M. L., Sharma, A., Floris-Moore, M., Topper, E. T., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae540 · Cited by 10
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Daar, E. S., Orkin, C. M., Sax, P. E., Hagins, D. P., Pozniak, A., Workowski, K., Brinson, C. C., Tiraboschi, J. M., Liu, H., Deaton, C., et al. (2025) · AIDS Research and Therapy · doi:10.1186/s12981-025-00732-w · Cited by 10
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population
Griesel, R., Sinxadi, P., Kawuma, A. N., Joska, J. A., Sokhela, S. M., Akpomiemie, G., Venter, F., Denti, P., Haas, D. W., & Maartens, G. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac290 · Cited by 10
Self-citation
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study
Bendala‐Estrada, A. D., Díaz‐Almirón, M., Busca, C., Micán, R. E., Cadiñanos, J., Montes, M., Martín‐Carbonero, L., Valencia, E., Montejano, R., Delgado‐Hierro, A., et al. (2022) · HIV Medicine · doi:10.1111/hiv.13432 · Cited by 10
Decreased Hepatic Steatosis in South African Adolescents With Perinatal HIV Switching to Dolutegravir-containing Regimens
Rose, P. C., Nel, E., Cotton, M. F., Otwombe, K. N., Browne, S. H., Frigati, L. J., Rabie, H., & Innes, S. (2023) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003904 · Cited by 10
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males
Zhang, Z., Lin, Q., Xu, Y., Guan, W., Song, X., Li, Y., Zhang, Y., Li, T., & Yu, W. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01238-6 · Cited by 10
Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania
Ntamatungiro, A. J., Eichenberger, A. L., Okuma, J. O., Vanobberghen, F. M., Ndege, R. C., Kimera, N., Francis, J. M., Kagura, J., Weisser, M., & for the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) Study Group (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad321 · Cited by 10
Correlates of physical activity among people living with and without HIV in rural Uganda
Mabweazara, S. Z., Manne‐Goehler, J., Bibangambah, P., Kim, J., Sentongo, R. N., Hemphill, L., Okello, S., Hamer, M., & Siedner, M. J. (2023) · Frontiers in Reproductive Health · doi:10.3389/frph.2023.1093298 · Cited by 10
Associations of HIV and antiretroviral therapy with gestational diabetes in South Africa
Bengtson, A. M., Madlala, H. P., Matjila, M. J., Levitt, N. S., Goedecke, J. H., Cu‐Uvin, S., McGarvey, S. T., Werner, E. F., & Myer, L. (2023) · AIDS · doi:10.1097/qad.0000000000003678 · Cited by 10
Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens
Wu, K., Koethe, J. R., Hulgan, T., Brown, T. T., Bares, S. H., Tassiopoulos, K., Lake, J. E., Leonard, M. A., Samuels, D. C., Erlandson, K. M., et al. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000515 · Cited by 10
Virological Non-Suppression, Non-Adherence and the Associated Factors Among People Living with HIV on Dolutegravir-Based Regimens: A Retrospective Cohort Study
Kabiibi, F., Tamukong, R., Muyindike, W. R., & Yadesa, T. M. (2024) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s449947 · Cited by 10
Impact of financial incentives on viral suppression among adults initiating HIV treatment in Tanzania: a hybrid effectiveness–implementation trial
Njau, P. F., Katabaro, E., Winters, S., Sabasaba, A. N., Hassan, K., Joseph, B., Maila, H., Msasa, J., Fahey, C. A., Packel, L. J., et al. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(24)00149-8 · Cited by 10

Authors: Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B., & Hill, A.
Affiliations: From Ezintsha (W.D.F.V., M. Moorhouse, S.S., N.M., C.S., G.A., N.C., N.A., A.V.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences (W.D.F.V., M. Moorhouse, S.S., L.F., N.M., M. Masenya, C.S., G.A., N.C., M.C., N.A., A.V.), and the South African Medical Research Council Developmental Pathways for Health Research Unit, Department of Pediatrics, School of Clinical Medicine, Faculty of Health Sciences (S.N.), University of the Witwatersrand, Johannesburg; the Faculty of Medicine,...
South African Medical Research Council (ZA)
ORCID: Venter, Willem D.F.
Moorhouse, Michelle
Sokhela, Simiso
Fairlie, Lee
Mashabane, Nkuli
Masenya, Masebole
Serenata, Celicia
Akpomiemie, Godspower
Qavi, Ambar
Chandiwana, Nomathemba
Norris, Shane
Chersich, Matthew
Clayden, Polly
Abrams, Elaine
Arulappan, Natasha
Vos, Alinda
McCann, Kaitlyn
Simmons, Bryony
Hill, Andrew
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-08-29
Volume: 381
Issue: 9
Pages: 803-815
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1902824
OpenAlex: W2962964639
Cited by: 723
References: 31
Citations by year: 2026: 65 · 2025: 84 · 2024: 117 · 2023: 110 · 2022: 90 · 2021: 112 · 2020: 120 · 2019: 25
FWCI: 66.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
ePrints Soton (University of Southampton) (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion)
Funders: UNITAID (2016-07-Wits RHI)
U.S. Agency for International Development (AID-OAA-A-15-00069)
South African Medical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: dolutegravir, tenofovir alafenamide, tenofovir disoproxil fumarate, HIV-1 infection, antiretroviral therapy, triple therapy, emtricitabine, efavirenz, non-inferiority, viral suppression, treatment discontinuation, low- and middle-income countries, South Africa
MeSH terms: Dolutegravir, Adenine, Adolescent, Adult, Drug Therapy, Combination, Female, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Oxazines, Phosphorous Acids, Piperazines, Pregnancy, Pregnancy Complications, Infectious, Prodrugs, Pyridones, RNA, Viral, Uracil, HIV-1, Bone Density, HIV Infections, CD4 Lymphocyte Count, HIV Integrase Inhibitors, Viral Load, Anti-Retroviral Agents, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks